Literature DB >> 18258742

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Muhammad Emaduddin1, David C Bicknell, Walter F Bodmer, Stephan M Feller.   

Abstract

The heterogeneity of cancer cell signaling is a significant obstacle for the effective development and clinical use of molecularly targeted therapies. As a contribution to a better understanding of the diversity of signaling activities in colorectal cancers (CRCs), we have analyzed the activity of Src family kinases (SFKs), which are implicated in human cancer development, in 64 CRC cell lines. A striking diversity of SFK activity was observed within this panel. Importantly, all CRC lines tested depend on SFK activity for their growth. In addition, SFK activity levels strongly correlated with global levels of tyrosine-phosphorylated (pTyr) proteins in CRC lines. SFK inhibition substantially reduced these pTyr levels, suggesting that SFKs may function as signal integration points and master controllers for the pTyr protein status in CRC lines. The majority of analyzed CRC lines with high-SFK activity express activated c-Met (pYpY1234/1235), a receptor tyrosine kinase contributing to the regulation of cell proliferation, migration, and invasion. Inhibition of SFKs reduced c-Met phosphorylation in most cases, indicating a reversed signal flow from SFK to c-Met. We conclude that SFK activity is important for the growth of CRC lines, although only low activity levels are required. If this also is true for CRC patients, tumors with low-SFK activity may be particularly sensitive to SFK inhibitors, and such patients should be targeted in clinical trials testing SFK inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258742      PMCID: PMC2268141          DOI: 10.1073/pnas.0712176105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Met, metastasis, motility and more.

Authors:  Carmen Birchmeier; Walter Birchmeier; Ermanno Gherardi; George F Vande Woude
Journal:  Nat Rev Mol Cell Biol       Date:  2003-12       Impact factor: 94.444

Review 2.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

3.  Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.

Authors:  Heike Aligayer; Douglas D Boyd; Markus M Heiss; Eddie K Abdalla; Steven A Curley; Gary E Gallick
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

4.  Human colonic adenocarcinoma cells. I. Establishment and description of a new line.

Authors:  B H Tom; L P Rutzky; M M Jakstys; R Oyasu; C I Kaye; B D Kahan
Journal:  In Vitro       Date:  1976-03

5.  The specificities of protein kinase inhibitors: an update.

Authors:  Jenny Bain; Hilary McLauchlan; Matthew Elliott; Philip Cohen
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

Review 6.  c-Src and cooperating partners in human cancer.

Authors:  Rumey Ishizawar; Sarah J Parsons
Journal:  Cancer Cell       Date:  2004-09       Impact factor: 31.743

Review 7.  Src family kinases in tumor progression and metastasis.

Authors:  Justin M Summy; Gary E Gallick
Journal:  Cancer Metastasis Rev       Date:  2003-12       Impact factor: 9.264

8.  Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.

Authors:  Gillian Smith; Francis A Carey; Julie Beattie; Murray J V Wilkie; Tracy J Lightfoot; Jonathan Coxhead; R Colin Garner; Robert J C Steele; C Roland Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

9.  Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro.

Authors:  Madhavi Sekharam; Aejaz Nasir; Hans E Kaiser; Domenico Coppola
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

Review 10.  Tyrosine kinase signalling in breast cancer.

Authors:  N E Hynes
Journal:  Breast Cancer Res       Date:  2000-04-17       Impact factor: 6.466

View more
  30 in total

1.  A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.

Authors:  Craig W Menges; Yibai Chen; Brooke T Mossman; Jonathan Chernoff; Anthony T Yeung; Joseph R Testa
Journal:  Genes Cancer       Date:  2010-05-01

2.  The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.

Authors:  Mike R Russell; Qingxin Liu; Hetian Lei; Andrius Kazlauskas; Alessandro Fatatis
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

3.  Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3).

Authors:  Evgenia Rouka; Philip C Simister; Melanie Janning; Joerg Kumbrink; Tassos Konstantinou; João R C Muniz; Dhira Joshi; Nicola O'Reilly; Rudolf Volkmer; Brigitte Ritter; Stefan Knapp; Frank von Delft; Kathrin H Kirsch; Stephan M Feller
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

4.  Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts.

Authors:  Audrey Sirvent; Oana Vigy; Beatrice Orsetti; Serge Urbach; Serge Roche
Journal:  Mol Cell Proteomics       Date:  2012-09-29       Impact factor: 5.911

5.  Gene expression profile comparison between colorectal cancer and adjacent normal tissues.

Authors:  Qian Yang; Maohui Feng; Xiang Ma; Huachi Li; Wei Xie
Journal:  Oncol Lett       Date:  2017-09-08       Impact factor: 2.967

6.  High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells.

Authors:  Theresia R Kress; Thomas Raabe; Stephan M Feller
Journal:  Cell Commun Signal       Date:  2010-02-02       Impact factor: 5.712

7.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

8.  Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.

Authors:  Rebecca E Schweppe; Anna A Kerege; Jena D French; Vibha Sharma; Rachel L Grzywa; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

9.  The dawn of a new era in cell signalling research.

Authors:  Stephan M Feller
Journal:  Cell Commun Signal       Date:  2010-05-24       Impact factor: 5.712

10.  Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.

Authors:  Tim P Green; Mike Fennell; Robin Whittaker; Jon Curwen; Vivien Jacobs; Jack Allen; Armelle Logie; Judith Hargreaves; D Mark Hickinson; Robert W Wilkinson; Paul Elvin; Brigitte Boyer; Neil Carragher; Patrick A Plé; Alun Bermingham; Geoffrey A Holdgate; Walter H J Ward; Laurent F Hennequin; Barry R Davies; Gerard F Costello
Journal:  Mol Oncol       Date:  2009-02-07       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.